Table 1

Demographic data and initial treatment strategies of the 7831 patients with a recent diagnosis of RA available to work at baseline

Year cohort
Variable2000–1 (N=1998) N (%)2002–3 (N=2043) N (%)2004–5 (N=1871) N (%)2006–7 (N=1919) N (%)p for linearity
Female (%)1422 (71)1462 (72)1291 (69)1377 (72)0.86
Age on index day, mean (SD)45 (11)46 (11)47 (10)46 (11)<0.001
RF present (%)1135 (57)1235 (60)1161 (62)1242 (65)<0.001
Incidence of RA in the 18–64-year-old population/100 000 per year (95% CI)39 (37 to 40)39 (38 to 41)36 (35 to 38)36 (35 to 38)<0.001*
Initial treatment (≤3 months)
 No DMARDs149 (7)171 (8)145 (8)113 (6)0.045
 Any single DMARD1072 (53)1004 (49)750 (40)708 (36)<0.001
 Single MTX166 (8)196 (10)243 (13)295 (15)
 Any combination DMARDs781 (39)877 (43)989 (53)1105 (58)<0.001
 Combination including MTX502 (25)651 (32)801 (43)925 (48)
 Adalimumab or etanercept initiated at any time while available to work79 (4)84 (4)85 (5)29 (2)NA
  • * Age- and sex-adjusted.

  • DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; NA, not applicable; RA, rheumatoid arthritis.